Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast Cancer
Fangyuan Chen, Sayali Onkar, Jian Zou, Yujia Li, Haley Arbore, Sai Maley, George Tseng, Peter Lucas, Tullia Bruno, Dario Vignali, Julia Foldi, Marija Balic, Adrian Lee, Steffi Oesterreich

TL;DR
This study finds that immune cell presence in a specific type of breast cancer correlates with different genetic patterns, which could help predict patient outcomes.
Contribution
The study identifies novel transcriptomic subtypes and immune infiltration patterns specific to ER+/HER2- invasive lobular breast cancer.
Findings
Two transcriptomic subtypes and five immune infiltration patterns were identified in ER+/HER2- invasive lobular breast cancer.
A TAM-Low signature correlates with lower infiltration of pro-inflammatory TAM and better patient outcomes in ER+ tumors.
Abstract
Understanding interplay of breast cancer and microenvironment is critical. Here, we identified two transcriptomic subtypes and five immune infiltration patterns from RNA-seq and multiplex immunohistochemistry from 21 ER+/HER2- invasive lobular breast cancers. The proliferative subtype associated with increased immune infiltration especially by immunosuppressive regulatory T-cells and macrophages. We also defined a TAM-Low signature, which associated with lower infiltration of proliferative, pro-inflammatory TAM, and improved outcome in patients with ER+ tumors.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Immunotherapy and Biomarkers · Single-cell and spatial transcriptomics · Ferroptosis and cancer prognosis
